Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.


Opinion: NJAMHAA Mary Abrams Urges NJ’s Members of Congress to Reject GOP Interference with Medicare Part D

New Brunswick, NJ, July 13, 2017In a Star-Ledger opinion piece published on July 12, Mary Abrams, Senior Health Policy Analyst at the New Jersey Association of Mental Health and Addiction Agencies (NJAMHAA), writes:

Congress could soon weaken prescription drug coverage for more than 900,000 New Jersey residents.  Lawmakers want to fundamentally alter Medicare Part D, which has provided seniors and the disabled with affordable medicines for more than a decade.

The program has become a lifeline.  Without Part D, nearly two out of three seniors say that they would be unable to fill all of their prescriptions, while one in two say that they would be more likely to cut back or stop taking their medicines altogether. Continue reading

Study: Medicare Prescription Drug Benefit Reduced Elderly Mortality by 2.2 Percent

Champaign, IL, March 15, 2017 — A new paper co-written by a University of Illinois expert in health care economics provides the first evidence that the increase in drug utilization attributable to Medicare Part D saved lives.

The implementation of Medicare’s prescription drug benefit program has reduced elderly mortality by 2.2 percent annually since 2006, according to an analysis by Julian Reif, a professor of finance and of economics at Illinois.

“A big question in health economics is ‘Do public health insurance programs improve people’s health?’” said Reif, also a faculty member of the Institute of Government and Public Affairs and the Center for Business and Public Policy. Continue reading

New Jersey Policy Perspective Reports: An Obamacare Repeal Without Replacement Will ‘Devastate’ the Garden State

Trenton, NJ, February 22, 2017 — According to a new report from the New Jersey Policy Perspective, if Congress repeals the Affordable Care Act (ACA) — well known as Obamacare — and doesn’t replace it, the loss of coverage for an estimated 800,000 New Jersey residents would be only part of the story, reports Lindy Washburn in The Record/NorthJersey.com.

The report presents county-by-county data about the effect of ACA repeal.

In addition, Livio reports that more than 210,000 seniors who rely on Medicare and have substantial prescription drug needs would face higher out-of-pocket costs. Continue reading

Study: Costs for Most Long-Term Care, Home Health Aides and Assisted Living Keep Climbing

Nursing home 3Washington, DC, May 11, 2016 ― The Associated Press reports that long-term care grew more expensive again this year, with the cost of the priciest option, a private nursing home room, edging closer to $100,000 annually, according to a survey from Genworth Financial.

Americans also are paying more for other care options like home health aides and assisted living communities, while adult day care costs fell slightly compared to 2015, Genworth reported in a study released Tuesday.

Private nursing home rooms now come with a median annual bill of $92,378, an increase of 1.2 percent from last year and nearly 19 percent since 2011.  That’s roughly twice the rate of overall inflation and breaks down to a monthly bill of $7,698. Continue reading

New Study: Older Americans Taking More Medications and Supplements

Senior at Pharmacy 2New York, NY, March 24, 2016 ― Reuters’ Andrew M. Seaman reports that the proportion of older Americans taking at least five medications or supplements went up in a recent study.

The increase in people using multiple medications — known as polypharmacy — paralleled an increase in the number of older Americans at risk for major drug interactions, researchers found.

“That’s a concern from a public health standpoint, because it’s getting worse,” said Dima Qato, the study’s lead author from the University of Illinois at Chicago. Continue reading

HHS Reports People with Medicare Have Saved Over $20 Billion on Prescription Drugs Since 2010; Jerseyans Saved $1 Billion

Baltimore, MD, February 9, 2016 ― The Department of Health and Human Services released yesterday new information that shows that millions of seniors and people with disabilities with Medicare continue to save on prescription drugs and see improved benefits in 2015 as a result of the Affordable Care Act.

Nearly 10.7 million Medicare beneficiaries have received discounts over $20.8 billion on prescription drugs — an average of $1,945 per beneficiary — since the enactment of the Affordable Care Act of 2010.

According to state-by-state information on discounts, New Jersey senior and people with disabilities received a total discount of $1.04 billion since the enactment of the Affordable Care Act. Continue reading

Senators Launch Investigation into Prescription Drug Pricing; Request Documents from Four Companies

Senators Susan Collins and Claire McCaskill

Senators Susan Collins and Claire McCaskill

Washington, DC, November 4, 2015 ― U.S. Senators Susan Collins (R-Maine) and Claire McCaskill (D-Mo.), who together lead the Senate Special Committee on Aging, today announced a bipartisan Senate investigation into pharmaceutical drug pricing.

The announcement follows a series of media reports detailing dramatic drug price increases—often on older, off-patent drugs—after the acquisition or merger of pharmaceutical companies.

Chairman Collins said, “The sudden, aggressive price hikes for a variety of drugs used widely for decades affect patients and health care providers and the overall cost of health care. These substantial increases have the potential to inflate the cost of health care for Americans, especially our seniors, by hundreds of millions of dollars each year.” Continue reading

PhRMA Report: 465 Medicines in Development for Chronic Diseases Affecting Seniors

Washington, DC, March 21, 2013 — America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditions affecting seniors, according to a new report and overview released yesterday by the Pharmaceutical Research and Manufacturers of America (PhRMA).

 With the population of Americans over 65 on the rise and life expectancy climbing, chronic diseases remain a principal threat to the health and productivity of older Americans, as well as to rising health care costs.  Innovative medicines have led to major advances against many chronic diseases ― and the robust discovery pipeline of new medicines portends continued progress for seniors and our health care system. Continue reading